Update on Research and Treatment of Premenstrual Dysphoric Disorder

REFERENCES

• Borenstein J, Chiou C F, Dean B, Wong J, Wade S. Estimating direct and indirect costs of premenstrual syndrome. J Occup Environ Med 2005; 47: 26–33
   PubMed Web of Science ®Google Scholar
• Deuster P, Adera T, South-Paul J. Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 1999; 8: 122–8
   PubMedGoogle Scholar
• Johnson S, McChesney C, Bean J. Epidemiology of premenstrual symptoms in a nonclinical sample. I. Prevalence, natural history and help-seeking behavior. J Reprod Med 1988; 33: 340–6
   PubMed Web of Science ®Google Scholar
• Meaden P, Hartlage S, Cook-Kerr J. Timing and severity of symptoms associated with the menstrual cycle in a community-based sample in the Midwestern United States. Psychiatry Res 2005; 134: 27–36
   PubMed Web of Science ®Google Scholar
• Wood C, Larsen L, Williams R. Menstrual characteristics of 2343 women attending the Shepherd Foundation. Aust N Z J Obstet Gynaecol 1979; 19: 107–10
   PubMed Web of Science ®Google Scholar
• Angst J, Sellaro R, Merikangas K, Endicott J. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 2001; 104: 110–6
   PubMed Web of Science ®Google Scholar
• Borenstein J E, Dean B B, Leifke E, Korner P, Yonkers K A. Differences in symptom scores and health outcomes in premenstrual syndrome. J Womens Health 2007; 16: 1139–44
   PubMed Web of Science ®Google Scholar
• Yang M, Wallenstein G, Hagan M, Guo A, Chang J, Kornstein S. Burden of premenstrual dysphoric disorder on health-related quality of life. J Womens Health 2008; 17: 113–21
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. APA, Washington, DC 1994
   Google Scholar
• Yonkers K A, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 1997; 278: 983–8, comment 1024–5
   PubMed Web of Science ®Google Scholar
• Hylan T, Sundell K, Judge R. The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom, and France. J Womens Health Gend Based Med 1999; 8: 1043–52
   PubMed Web of Science ®Google Scholar
• Pearlstein T, Halbreich U, Batzar E, et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000; 61: 101–9
   PubMed Web of Science ®Google Scholar
• Borenstein J, Dean B, Endicott J, et al. Health and economic impact of the premenstrual syndrome. J Reprod Med 2003; 48: 515–24
   PubMed Web of Science ®Google Scholar
• Campbell E M, Peterkin D, O'Grady K, Sanson-Fisher R. Premenstrual symptoms in general practice patients. Prevalence and treatment. J Reprod Med 1997; 42: 637–46
   PubMed Web of Science ®Google Scholar
• Wittchen H U, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002; 32: 119–32
   PubMed Web of Science ®Google Scholar
• Chaturvedi S K, Chandra P S, Gururaj G, Pandian R D, Beena M B. Suicidal ideas during premenstrual phase. J Affect Disord 1995; 34: 193–9
   Google Scholar
• Stout A L, Steege J F, Blazer D G, George L K. Comparison of lifetime psychiatric diagnoses in premenstrual syndrome clinic and community samples. J Nerv Ment Dis 1986; 174: 517–22
   PubMed Web of Science ®Google Scholar
• Halbreich U, Borenstein J, Pearlstein T, Kahn L. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003; 28(suppl 3)1–23
   Google Scholar
• Halbreich U, Backstrom T, Eriksson E, et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol 2007; 23: 123–30
   PubMed Web of Science ®Google Scholar
• Yonkers K, Steiner M. Depression in women. Dunitz, London 1999
   Google Scholar
• Hurt S W, Schnurr P P, Severino S K, et al. Late luteal phase dysphoric disorder in 670 women evaluated for premenstrual complaints. J Am Psychiatry 1992; 149: 525–30
   PubMed Web of Science ®Google Scholar
• Di Giulio G, Reissing E D. Premenstrual dysphoric disorder: prevalence, diagnostic considerations, and controversies. J Psychosom Obstet Gynaecol 2006; 27: 201–10
   PubMed Web of Science ®Google Scholar
• ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin. Premenstrual syndrome. Number 15, April 2000. Int J Gynaecol Obstet 2001; 73: 183–91
   Google Scholar
• Ross L E, Steiner M. A biopsychosocial approach to premenstrual dysphoric disorder. Psychiatr Clin North Am 2003; 26: 529–46
   PubMed Web of Science ®Google Scholar
• Perkonigg A, Yonkers K, Pfiste H, Lieb R, Wittchen H U. Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. J Clin Psychiatry 2004; 65: 1314–22
   PubMed Web of Science ®Google Scholar
• Girdler S S, Thompson K S, Light K C, Leserman J, Pedersen C A, Prange A J, Jr. Historical sexual abuse and current thyroid axis profiles in women with premenstrual dysphoric disorder. Psychosom Med 2004; 66: 403–10
   Google Scholar
• Girdler S S, Klatzkin R. Neurosteroids in the context of stress: implications for depressive disorders. Pharmacol Ther 2007; 116: 125–39
   PubMed Web of Science ®Google Scholar
• Bunevicius R, Hinderliter A L, Light K C, Leserman J, Pedersen C A, Girdler S S. Histories of sexual abuse are associated with differential effects of clonidine on autonomic function in women with premenstrual dysphoric disorder. Biol Psychol 2005; 69: 281–96
   Google Scholar
• Koci A, Strickland O. Relationship of adolescent physical and sexual abuse to perimenstrual symptoms (PMS) in adulthood. Issues Ment Health Nurs 2007; 28: 75–87
   PubMedGoogle Scholar
• Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health 2006; 9: 41
   PubMed Web of Science ®Google Scholar
• Borenstein J E, Dean B B, Yonkers K A, Endicott J. Using the daily record of severity of problems as a screening instrument for premenstrual syndrome. Obstet Gynecol 2007; 109: 1068–75
   PubMed Web of Science ®Google Scholar
• Mortola J F, Girton L, Beck L, Yen S S. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences. Obstet Gynecol 1990; 76: 302–7
   PubMed Web of Science ®Google Scholar
• Moos R H. The development of a menstrual distress questionnaire. Psychosom Med 1968; 30: 853–67
   PubMed Web of Science ®Google Scholar
• Endicott J, Halbreich U. Retrospective report of premenstrual depressive changes. Psychopharmacol Bull 1982; 18: 109–12
   Google Scholar
• Reid R. Premenstrual syndrome. Curr Probl Obstet Gynecol Fertil 1985; 8: 1
   Google Scholar
• Yonkers K A, O'Brien P MS, Eriksson E. Premenstrual syndrome. Lancet 2008; 371: 1200–10
   PubMed Web of Science ®Google Scholar
• Woods N, Most A, Dery G. Prevalence of perimenstrual symptoms. J Am Public Health 1982; 72: 1257–64
   PubMed Web of Science ®Google Scholar
• Andersch B, Wendestam C, Hahn L, Ohman R. Premenstrual complaints. Prevalence of premenstrual symptoms in a Swedish urban population. J Psychosom Obstet Gynaecol 1986; 5: 39–49
   Google Scholar
• Ramcharan S, Love E J, Fick G H, Goldfien A. The epidemiology of premenstrual symptoms in a population based sample of 2650 urban women: attributable risk and risk factors. J Clin Epidemiol 1992; 45: 377–81
   PubMed Web of Science ®Google Scholar
• Rivera-Tovar A D, Frank E. Late luteal phase dysphoric disorder in young women. J Am Psychiatry 1990; 147: 1634–6
   PubMed Web of Science ®Google Scholar
• Soares C N, Cohen L S, Otto M W, Harlow B L. Characteristics of women with premenstrual dysphoric disorder (PMDD) who did or did not report history of depression: a preliminary report from the Harvard Study of Moods and Cycles. J Womens Health Gend Based Med 2001; 10: 873–8
   PubMedGoogle Scholar
• Takeda T, Tasaka K, Sakata M, Murata Y. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in Japanese women. Arch Womens Ment Health 2006; 9: 209–12
   PubMed Web of Science ®Google Scholar
• Pearlstein T, Yonkers K, Fayyad R, Gillespie J. Pretreatment pattern of symptom expression in premenstrual dsyphoric disorder. J Affect Disord 2005; 85: 275–82
   PubMed Web of Science ®Google Scholar
• Sternfeld B, Swindle R, Chawla A, Long S, Kennedy S. Severity of premenstrual symptoms in a health maintenance organization population. Obstet Gynecol 2002; 99: 1014–24
   PubMed Web of Science ®Google Scholar
• Bloch M, Schmidt P, Rubinow D. Premenstrual syndrome: evidence for symptom stability across cycles. J Am Psychiatry 1997; 154: 1741–6
   PubMed Web of Science ®Google Scholar
• Condon J T. The premenstrual syndrome: a twin study. J Br Psychiatry 1993; 162: 481–6
   PubMed Web of Science ®Google Scholar
• Kendler K, Karkowski L, Corey L, Neale M. Longitudinal population-based study of retrospectively reported premenstrual symptoms and lifetime major depression. J Am Psychiatry 1998; 155: 1234–40
   PubMed Web of Science ®Google Scholar
• Treloar S, Heath A M, Martin N G. Genetic and environmental influences on premenstrual symptoms in an Australian twin sample. Psychol Med 2002; 32: 25–38
   PubMed Web of Science ®Google Scholar
• Dhingra V, Magnay J L, O'Brien P M, Chapman G, Fryer A A, Ismail K M. Serotonin receptor 1A C(-1019)G polymorphism associated with premenstrual dysphoric disorder. Obstet Gynecol 2007; 110: 788–92
   PubMedGoogle Scholar
• Huo L, Straub R E, Roca C, et al. Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. Biol Psychiatry 2007; 62: 925–33
   PubMed Web of Science ®Google Scholar
• Masho S W, Adera T, South-Paul J. Obesity as a risk factor for premenstrual syndrome. J Psychosom Obstet Gynaecol 2005; 26: 33–9
   PubMed Web of Science ®Google Scholar
• Nakamoto Y, Sato M, Miwa M, Murakami M, Yoshii M. Impaired reactivity to mental stress in premenstrual dysphoric disorder [PMDD] patients. Neurosci Res 2007; 58(suppl 1)S165
   Google Scholar
• Girdler S S, Leserman J, Bunevicius R, Klatzkin R, Pedersen C A, Light K C. Persistent alterations in biological profiles in women with abuse histories: influence of premenstrual dysphoric disorder. Health Psychol 2007; 26: 201–13
   Google Scholar
• Rosseinsky D, Debonne L P. An evolutionary theory of premenstrual tension. Lancet 1974; 2: 1024
   PubMed Web of Science ®Google Scholar
• Castellanos F, Orihuela A, Galina C S. Aggressive behaviour in oestrus and dioestrus dairy cows and heifers. J Reprod Fertil 1973; 34: 509–11
   Google Scholar
• Floody O, Pfaff D. Aggressive behaviour in female hamsters: the hormonal basis for fluctuations in female aggressiveness correlated with estrous state. J Comp Physiol Psychol 1977; 91: 443–64
   Google Scholar
• Garcia-Castell E, Juarez Gonzalez J, Ervin F, Guzman-Flores C. Changes in the social dynamics associated to the menstrual cycle in the vervet monkey. Bol Estud Med Biol 1989; 37: 11–6
   Google Scholar
• Rapkin A, Pollack D, Raleigh M, Stone B, McGuire M T. Menstrual cycle and social behavior in vervet monkeys. Psychoneuroendocrinology 1995; 20: 289–97
   PubMed Web of Science ®Google Scholar
• Ho H, Olsson M, Westberg L, Melke J, Eriksson E. The serotonin reuptake inhibitor fluoxetine reduces sex steroid-related aggression in female rats: an animal model of premenstrual irritability?. Neuropsychopharmacology 2001; 24: 502–10
   PubMed Web of Science ®Google Scholar
• Hyde J, Sawyer T. Estrous cycle fluctuations in aggressiveness of house mice. Horm Behav 1977; 9: 290–5
   Google Scholar
• Schneider T, Popik P. Increased depressive-like traits in an animal model of premenstrual irritability. Horm Behav 2007; 51: 142–8
   Google Scholar
• Marvan M L, Chavez-Chavez L, Santana S. Clomipramine modifies fluctuations of forced swimming immobility in different phases of the rat estrous cycle. Arch Med Res 1996; 27: 83–6
   Google Scholar
• Beckley E H, Finn D A. Inhibition of progesterone metabolism mimics the effect of progesterone withdrawal on forced swim test immobility. Pharmacol Biochem Behav 2007; 87: 412–9
   Google Scholar
• MacDonald P, Dombroski R, Casey M. Recurrent secretion of progesterone in large amounts: an endocrine/metabolic disorder unique to young women?. Endocr Rev 1991; 12: 372–401
   PubMed Web of Science ®Google Scholar
• Frank R. The hormonal causes of premenstrual tension. Arch Neurol Psychiatry 1931; 26: 1053–7
   Google Scholar
• Hammarback S, Ekholm U-B, Backstrom T. Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinol (Copenh) 1991; 125: 132–7
   PubMedGoogle Scholar
• Casper R, Hearn M. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. J Am Obstet Gynecol 1990; 162: 105–9
   PubMed Web of Science ®Google Scholar
• Casson P, Hahn P, Van Vugt D, Reid R. Lasting response to ovariectomy in severe intractable premenstrual syndrome. J Am Obstet Gynecol 1990; 162: 99–105
   PubMed Web of Science ®Google Scholar
• Studd J, Panay N. Hormones and depression in women. Climacteric 2004; 7: 338–46
   PubMed Web of Science ®Google Scholar
• Studd J, Smith R. Estrogens and depression in women. Menopause 1994; 1: 33–7
   Web of Science ®Google Scholar
• Cronje W H, Vashisht A, Studd J WW. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod 2004; 19: 2152–5
   PubMed Web of Science ®Google Scholar
• Muse K, Cetel N, Futterman L, Yen S. The premenstrual syndrome: effects of “medical ovariectomy.”. N J Engl Med 1984; 311: 1345–9
   PubMed Web of Science ®Google Scholar
• Bancroft J, Boyle H, Warner P, Fraser H M. The use of an LHRH agonist, buserelin, in the long-term management of premenstrual syndromes. Clin Endocrinol (Oxf) 1987; 27: 171–82
   PubMed Web of Science ®Google Scholar
• Hammarback S, Backstrom T. Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand 1988; 67: 159–66
   PubMed Web of Science ®Google Scholar
• Sundstrom I, Nyberg S, Bixo M S H, Backstrom T. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet Gynecol Scand 1999; 78: 891–9
   PubMed Web of Science ®Google Scholar
• Wyatt K, Dimmock P, Ismail K, Jones P, O'Brien P. The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: a meta analysis. BJOG 2004; 6: 585–93
   Google Scholar
• Birzniece V, Backstrom T, Johansson I M, et al. Neuroactive steroid effects on cognitive functions with a focus on the serotonin and GABA systems. Brain Res Rev 2006; 51: 212–39
   PubMedGoogle Scholar
• Smith S, Gong Q, Hsu F, Markowitz R, French-Mullen J, Li X. GABA A receptor alpha-4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature 1998; 392: 926–30
   PubMed Web of Science ®Google Scholar
• Smith S, Ruderman Y, Frye C, Homanics G, Yuan M. Steroid withdrawal in the mouse results in anxiogenic effects of 3alpha, 5beta-THP: a possible model of premenstrual dysphoric disorder. Psychopharmacology (Berl) 2006; 186: 323–33
   PubMed Web of Science ®Google Scholar
• Sundstrom Poromaa I, Smith S, Gulinello M. GABA receptors, progesterone and premenstrual dysphoric disorder. Arch Womens Ment Health 2003; 6: 23–41
   PubMedGoogle Scholar
• Griffiths J, Lovick T. Withdrawal from progesterone increases expression of alpha4, beta1, and delta GABA(A) receptor subunits in neurons in the periaqueductal gray matter in female Wistar rats. J Comp Neurol 2005; 486: 89–97
   Google Scholar
• Backstrom T, Andersson A, Andree L, et al. Pathogenesis in menstrual cycle-linked CNS disorders. N Ann Y Acad Sci 2003; 1007: 42–53
   PubMed Web of Science ®Google Scholar
• Schmidt P, Nieman L, Danaceau M, Adams L, Rubinow D. Differential behavioral effects of gonadal steriods in women with and in those without premenstrual syndrome. N J Engl Med 1998; 338: 209–16
   PubMed Web of Science ®Google Scholar
• Wyatt K, Dimmock P, Jones P, Obhrai M, O'Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ 2001; 323: 776–80
   PubMed Web of Science ®Google Scholar
• van Wingen G, van Broekhoven F, Verkes R, et al. Progesterone selectively increases amygdala reactivity in women. Mol Psychiatry 2008; 13: 325–33
   PubMed Web of Science ®Google Scholar
• Magos A, Brewster E, Singh R, O'Dowd T, Brincat M, Studd J. The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome. J Br Obstet Gynaecol 1986; 93: 1290–6
   PubMedGoogle Scholar
• Hammarback S, Backstrom T, Holst J, von Schoultz B, Lyrenas S. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestagen postmenopausal replacement therapy. Acta Obstet Gynecol Scand 1985; 64: 393–7
   PubMed Web of Science ®Google Scholar
• Genazzani A R, Petraglia F, Bernardi F, et al. Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences. J Clin Endocrinol Metab 1998; 83: 2099–103
   PubMed Web of Science ®Google Scholar
• Bicikova M, Dibbelt L, Hill M, Hampl R, Starka L. Allopregnanolone in women with premenstrual syndrome. Horm Metab Res 1998; 30: 227–30
   PubMed Web of Science ®Google Scholar
• Rapkin A, Morgan M, Goldman L, Brann D, Simone D, Mahesh V. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997; 90: 709–14
   PubMed Web of Science ®Google Scholar
• Schmidt P, Purdy R, Moore P, Paul S, Rubinow D. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab 1994; 79: 1256–60
   PubMed Web of Science ®Google Scholar
• Sundstrom I, Ashbrook D, Backstrom T. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology 1997; 22: 25–38
   PubMed Web of Science ®Google Scholar
• Kaura V, Ingram C D, Gartside S E, Young A H, Judge S J. The progesterone metabolite allopregnanolone potentiates GABA(A) receptor-mediated inhibition of 5-HT neuronal activity. Eur Neuropsychopharmacol 2007; 17: 108–15
   Google Scholar
• Matsumoto K, Puia G, Dong E, Pinna G. GABA(A) receptor neurotransmission dysfunction in a mouse model of social isolation-induced stress: possible insights into a non-serotonergic mechanism of action of SSRIs in mood and anxiety disorders. Stress 2007; 10: 3–12
   PubMed Web of Science ®Google Scholar
• Thys-Jacobs S, McMahon D, Bilezikian J P. Differences in free estradiol and sex hormone-binding globulin in women with and without premenstrual dysphoric disorder. J Clin Endocrinol Metab 2008; 93: 96–102
   Google Scholar
• Schmidt P, Nieman L, Grover G, Muller K, Merriam G, Rubinow D. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N J Engl Med 1991; 324: 1174–9
   PubMed Web of Science ®Google Scholar
• Schmidt P. Depression, the perimenopause, and estrogen therapy. N Ann Y Acad Sci 2005; 1052: 27–40
   PubMed Web of Science ®Google Scholar
• Bjorn I, Sundstrom-Poromaa I, Bixo M, Nyberg S, Backstrom G, Backstrom T. Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. J Clin Endocrinol Metab 2003; 88: 2026–30
   PubMed Web of Science ®Google Scholar
• Schmidt P, Grover G, Roy-Byrne P, Rubinow D. Thyroid function in women with premenstrual syndrome. J Clin Endocrinol Metab 1993; 76: 671–4
   PubMedGoogle Scholar
• Girdler S, Pedersen C, Light K. Thyroid axis function during the menstral cycle in women with premenstrual syndrome. Psychoneuroendocrinology 1995; 20: 395–403
   PubMedGoogle Scholar
• Korzekwa M I, Lamont J A, Steiner M. Late luteal phase dysphoric disorder and the thyroid axis revisited. J Clin Endocrinol Metab 1996; 81: 2280–4
   Google Scholar
• Portella A T, Haaga D A, Rohan K J. The association between seasonal and premenstrual symptoms is continuous and is not fully accounted for by depressive symptoms. J Nerv Ment Dis 2006; 194: 833–7
   PubMedGoogle Scholar
• Dalgleish T, Rosen K, Marks M. Rhythm and blues: the theory and treatment of seasonal affective disorder. J Br Clin Psychol 1996; 35: 163–82
   PubMed Web of Science ®Google Scholar
• Parry B L, Berga S L, Kripke D F, et al. Altered waveform of plasma nocturnal melatonin secretion in premenstrual depression. Arch Gen Psychiatry 1990; 47: 1139–46
   PubMed Web of Science ®Google Scholar
• Parry B L, Newton R P. Chronobiological basis of female-specific mood disorders. Neuropsychopharmacology 2001; 25(5 suppl)S102–8
   Google Scholar
• Pehrsson M, Westberg L, Landén M, Ekman A. Stable serum levels of relaxin throughout the menstrual cycle: a preliminary comparison of women with premenstrual dysphoria and controls. Arch Womens Ment Health 2007; 10: 147–53
   Google Scholar
• Thys-Jacobs S, McMahon D, Bilezikian J P. Cyclical changes in calcium metabolism across the menstrual cycle in women with premenstrual dysphoric disorder. J Clin Endocrinol Metab 2007; 92: 2952–9
   PubMed Web of Science ®Google Scholar
• Thys-Jacobs S, McMahon D, Bilezikian J P. Lower insulin-like growth factor-1 concentrations in women with premenstrual dysphoric disorder. J Am Obstet Gynecol 2008; 198: 506
   Google Scholar
• Sherwood R, Rocks B, Stewart A, Saxton R. Magnesium and the premenstrual syndrome. Ann Clin Biochem 1986; 23: 667–70
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Borella P, Fioroni L, et al. Reduction of monocyte's magnesium in patients affected by premenstrual syndrome. J Psychosom Obstet Gynaecol 1990; 11: 221
   Web of Science ®Google Scholar
• Rosenstein D, Elin R, Hosseini J, Grover G, Rubinow D. Magnesium measures across the menstrual cycle in premenstrual syndrome. Biol Psychiatry 1994; 35: 557–61
   PubMedGoogle Scholar
• Steiner M, Pearlstein T. Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry 2000; 61(suppl 12)17–21
   PubMed Web of Science ®Google Scholar
• Lesch K, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527–31
   PubMed Web of Science ®Google Scholar
• Hariri A, Mattay V, Tessitore A, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002; 297: 400–3
   PubMed Web of Science ®Google Scholar
• Parsey R, Hastings R, Oquendo M, et al. Lower serotonin transporter binding potential in the human brain during major depressive episodes. J Am Psychiatry 2006; 163: 52–8
   PubMed Web of Science ®Google Scholar
• Eriksson E, Andersch B, Ho H, Landen M, Sundblad C. Diagnosis and treatment of premenstrual dysphoria. J Clin Psychiatry 2002; 63(suppl 7)16–23
   Google Scholar
• Schneider T, Popik P. Attenuation of estrous cycle-dependent marble burying in female rats by acute treatment with progesterone and antidepressants. Psychoneuroendocrinology 2007; 32: 651–9
   Google Scholar
• Carlsson M, Carlsson A. A regional study of sex differences in rat brain serotonin. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 53–61
   PubMed Web of Science ®Google Scholar
• Hiroi R, McDevitt R, Neumaier J. Estrogen selectively increases tryptophan hydroxylase-2 mRNA expression in distinct subregions of rat midbrain raphe nucleus: association between gene expression and anxiety behavior in the open field. Biol Psychiatry 2006; 60: 288–95
   PubMed Web of Science ®Google Scholar
• Rubinow D, Schmidt P, Roca C. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry 1998; 44: 839–50
   PubMed Web of Science ®Google Scholar
• Zhang L, Ma W, Barker J, Rubinow D. Sex differences in expression of serotonin receptors (subtypes 1A and 2A) in rat brain: a possible role of testosterone. Neuroscience 1999; 94: 251–9
   Google Scholar
• Bethea C, Lu N, Gundlah C, Streicher J. Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol 2002; 23: 41–100
   PubMed Web of Science ®Google Scholar
• Qiao M, Zhao Q, Zhang H, Wang H, Xue L, Wei S. Isolating with physical restraint low status female monkeys during luteal phase might make an appropriate premenstrual depression syndrome model. J Affect Disord 2007; 102: 81–91
   PubMedGoogle Scholar
• Brzezinski A, Wurtman J, Wurtman R, Gleason R, Greenfield J, Nader T. d-Fenfluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual depression. Obstet Gynecol 1990; 76: 296–300
   PubMed Web of Science ®Google Scholar
• Su T-P, Schmidt P, Danaceau M, Murphy D, Rubinow D. Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. J Clin Endocrinol Metab 1997; 82: 1220–8
   PubMed Web of Science ®Google Scholar
• Steinberg S, Annable L, Young S, Liyanage N. A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria. Biol Psychiatry 1999; 45: 313–20
   PubMed Web of Science ®Google Scholar
• Landen M, Eriksson O, Sundblad C, Andersch B, Naessen T, Erikkson E. Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology (Berl) 2001; 155: 292–8
   PubMed Web of Science ®Google Scholar
• Menkes D B, Coates D C, Fawcett J P. Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord 1994; 32: 37–44
   PubMed Web of Science ®Google Scholar
• Roca C, Schmidt P, Smith M, Danaceau M A, Murphy D L, Rubinow D. Effects of metergoline on symptoms in women with premenstrual dysphoric disorder. J Am Psychiatry 2002; 159: 1876–81
   PubMed Web of Science ®Google Scholar
• Inoue Y, Terao T, Iwata N, et al. Fluctuating serotonergic function in premenstrual dysphoric disorder and premenstrual syndrome: findings from neuroendocrine challenge tests. Psychopharmacology (Berl) 2007; 190: 213–9
   PubMedGoogle Scholar
• Bancroft J, Cook A, Davidson D, Bennie J, Goodwin G. Blunting of neuroendocrine responses to infusion of L-tryptophan in women with perimenstrual mood change. Psychol Med 1991; 21: 305–12
   PubMed Web of Science ®Google Scholar
• Eriksson O, Wall A, Marteinsdottir I, et al. Mood changes correlate to changes in brain serotonin precursor trapping in women with premenstrual dysphoria. Psychiatry Res 2006; 146: 107–16
   PubMed Web of Science ®Google Scholar
• Fitzgerald M, Malone K, Li S, et al. Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder. J Am Psychiatry 1997; 154: 556
   PubMed Web of Science ®Google Scholar
• Halbreich U, Tworek H. Altered serotonergic activity in women with dysphoric premenstrual syndromes. J Int Psychiatry Med 1993; 23: 1–27
   PubMed Web of Science ®Google Scholar
• Melke J, Westberg L, Landen M, et al. Serotonin transporter gene polymorphisms and platelet [3H] paroxetine binding in premenstrual dysphoria. Psychoneuroendocrinology 2003; 28: 446–58
   Google Scholar
• Rasgon N, McGuire M, Tanavoli S, Fairbanks L, Rapkin A. Neuroendocrine response to an intravenous L-tryptophan challenge in women with premenstrual syndrome. Fertil Steril 2000; 73: 144–9
   PubMed Web of Science ®Google Scholar
• Rojansky N, Halbreich U, Zander K, Barkai A, Goldstein S. Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol Obstet Invest 1991; 31: 146–52
   PubMed Web of Science ®Google Scholar
• Steege J F, Stout A L, Knight B S, Nemeroff C B. Reduced platelet tritium-labeled imipramine binding sites in women with premenstrual syndrome. J Am Obstet Gynecol 1992; 167: 168–72
   PubMed Web of Science ®Google Scholar
• Steiner M, Yatham L N, Coote M, Wilkins A, Lepage P. Serotonergic dysfunction in women with pure premenstrual dysphoric disorder: is the fenfluramine challenge test still relevant. Psychiatry Res 1999; 87: 107–15
   Google Scholar
• Yatham L, Barry S, Dinan T. Serotonin receptors, buspirone, and premenstrual syndrome. Lancet 1989; 1: 1447–8
   PubMedGoogle Scholar
• Jovanovic H, Cerin A, Karlsson P, Lundberg J, Halldin C, Nordstrom A L. A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. Psychiatry Res 2006; 148: 185–93
   PubMed Web of Science ®Google Scholar
• Epperson C, Haga K, Mason G, et al. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 2002; 59: 851–8
   PubMed Web of Science ®Google Scholar
• Girdler S, Straneva P, Light K, Pederson C, Morrow A. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry 2001; 49: 788–97
   PubMed Web of Science ®Google Scholar
• Schmidt P, Grover G, Rubinow D. Alprazolam in the treatment of premenstrual syndrome. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 1993; 50: 467–73
   PubMed Web of Science ®Google Scholar
• Bhagwagar Z, Wylezinska M, Taylor M, Jezzard P, Matthews P, Cowen P. Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. J Am Psychiatry 2004; 161: 368–70
   PubMed Web of Science ®Google Scholar
• Soderpalm B, Engel J. Involvement of the GABA A/benzodiazepine chloride ionophore receptor complex in the 5,7-DHT Induced anticonflict effect. Life Sci 1991; 49: 139–53
   Google Scholar
• Sundstrom I, Backstrom T. Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial. Psychoneuroendocrinology 1998; 23: 73–88
   PubMed Web of Science ®Google Scholar
• Pinna G, Costa E, Guidotti A. Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology (Berl) 2006; 186: 362–72
   PubMed Web of Science ®Google Scholar
• Griffin L, Mellon S. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci U S A 1999; 96: 13512–7
   PubMed Web of Science ®Google Scholar
• Batra M, Seres-Mailo J, Hanstock C, et al. Proton magnetic resonance spectroscopy measurement of brain glutamate levels in premenstrual dysphoric disorder. Biol Psychiatry 2007; 63: 1178–84
   Google Scholar
• Chuong C, Hsi B, Gibbons W. Periovulatory beta-endorphin levels in premenstrual syndrome. Obstet Gynecol 1994; 83: 755–60
   Google Scholar
• Chuong C, Coulam C, Kao P, Bergstralh E, Go V. Neuropeptide levels in premenstrual syndrome. Fertil Steril 1985; 44: 760–5
   PubMed Web of Science ®Google Scholar
• Giannini A, Martin D, Turner C. Beta-endorphin decline in late luteal phase dysphoric disorder. J Int Psychiatry Med 1990; 20: 279–84
   PubMed Web of Science ®Google Scholar
• Halbreich U, Endicott J. Possible involvement of endorphin withdrawal or imbalance in specific premenstrual syndromes and postpartum depression. Med Hypotheses 1981; 7: 1045–58
   PubMed Web of Science ®Google Scholar
• Reid R, Yen S. Premenstrual syndrome. J Am Obstet Gynecol 1981; 139: 85–104
   PubMed Web of Science ®Google Scholar
• Straneva P A, Maixner W, Light K C, Pedersen C A, Costello N L, Girdler S S. Menstrual cycle, beta-endorphins, and pain sensitivity in premenstrual dysphoric disorder. Health Psychol 2002; 21: 358–67
   PubMed Web of Science ®Google Scholar
• Joffe H, Kim D R, Foris J M, et al. Menstrual dysfunction prior to onset of psychiatric illness is reported more commonly by women with bipolar disorder than by women with unipolar depression and healthy controls. J Clin Psychiatry 2006; 67: 297–304
   PubMed Web of Science ®Google Scholar
• Young E A, Korszun A. The hypothalamic-pituitary-gonadal axis in mood disorders. Endocrinol Metab Clin North Am 2002; 31: 63–78
   PubMed Web of Science ®Google Scholar
• Kask K, Gulinello M, Backstrom T, Geyer M A, Sundstrom-Poromaa I. Patients with premenstrual dysphoric disorder have increased startle response across both cycle phases and lower levels of prepulse inhibition during the late luteal phase of the menstrual cycle. Neuropsychopharmacology 2008; 33: 2283–90
   Google Scholar
• Epperson C N, Pittman B, Czarkowski K A, Stiklus S, Krystal J H, Grillon C. Luteal-phase accentuation of acoustic startle response in women with premenstrual dysphoric disorder. Neuropsychopharmacology 2007; 32: 2190–8
   PubMed Web of Science ®Google Scholar
• Smith S S, Shen H, Gong Q H, Zhou X. Neurosteroid regulation of GABA(A) receptors: focus on the alpha4 and delta subunits. Pharmacol Ther 2007; 116: 58–76
   PubMed Web of Science ®Google Scholar
• Gulinello M, Gong Q, Smith S. Progesterone withdrawal increases the α 4 subunit of the GABA(A) receptor in male rats in association with anxiety and altered pharmacology: a comparison with female rats. Neuropharmacology 2002; 43: 701–14
   Google Scholar
• Rubinow D R, Smith M J, Schenkel L A, Schmidt P J, Dancer K. Facial emotion discrimination across the menstrual cycle in women with premenstrual dysphoric disorder (PMDD) and controls. J Affect Disord 2007; 104: 37–44
   PubMedGoogle Scholar
• Protopopescu X, Tuescher O, Pan H, et al. Toward a functional neuroanatomy of premenstrual dysphoric disorder. J Affect Disord 2008; 108: 87–94
   PubMed Web of Science ®Google Scholar
• Hsu S C, Liu C Y, Hsiao M C. A comparison of the Tridimensional Personality Questionnaire in premenstrual dysphoric disorder and major depressive disorder. Compr Psychiatry 2007; 48: 366–70
   PubMedGoogle Scholar
• Faratian B, Gaspar A, O'Brien P, Johnson I, Filshie G, Prescott P. Premenstrual syndrome: weight, abdominal swelling, and perceived body image. J Am Obstet Gynecol 1984; 150: 200–4
   PubMed Web of Science ®Google Scholar
• Andersch B, Hahn L, Andersson M, Isaksson B. Body water and weight in patients with premenstrual tension. J Br Obstet Gynaecol 1978; 85: 546–50
   PubMedGoogle Scholar
• Andersch B. Bromocriptine and premenstrual symptoms: a survey of double blind trials. Obstet Gynecol Surv 1983; 38: 643–6
   PubMedGoogle Scholar
• Ylostalo P, Kauppila A, Puolakka J, Ronnberg L, Janne O. Bromocriptine and norethisterone in the treatment of premenstrual syndrome. Obstet Gynecol 1982; 59: 292–8
   PubMedGoogle Scholar
• Wuttke W, Jarry H, Christoffel V, Spengler B, Seidlova-Wuttke D. Chaste tree (Vitex agnus-castus)—pharmacology and clinical indications. Phytomedicine 2003; 10: 348–57
   PubMed Web of Science ®Google Scholar
• O'Brien P, Abukhalil I. Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase–only danazol. J Am Obstet Gynecol 1999; 180: 18–23
   PubMed Web of Science ®Google Scholar
• Oksa S, Luukkaala T, Maenpaa J. Toremifene for premenstrual mastalgia: a randomised, placebo-controlled crossover study. BJOG 2006; 113: 713–8
   Google Scholar
• O'Brien P, Craven D, Selby C, et al. Treatment of premenstrual syndrome by spironolactone. J Br Obstet Gynaecol 1979; 86: 142–7
   PubMedGoogle Scholar
• Rosenfeld R, Livne D, Nevo O, et al. Hormonal and volume dysregulation in women with premenstrual syndrome. Hypertension 2008; 51: 1225–30
   PubMed Web of Science ®Google Scholar
• Tietjen G E, Bushnell C D, Herial N A, Utley C, White L, Hafeez F. Endometriosis is associated with prevalence of comorbid conditions in migraine. Headache 2007; 47: 1069–78
   PubMed Web of Science ®Google Scholar
• Moja P, Cusi C, Sterzi R, Canepari C. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev Jul, 2005; 20(3), CD002919
   Google Scholar
• Bancroft J, Rennie D. Perimenstrual depression: its relationship to pain, bleeding, and previous history of depression. Psychosom Med 1995; 57: 445–52
   Google Scholar
• Steiner M, Born L. Diagnosis and treatment of premenstrual dysphoric disorder: an update. Int Clin Psychopharmacol 2000; 15(suppl 3)S5–17
   PubMed Web of Science ®Google Scholar
• Kim D R, Gyulai L, Freeman E W, Morrison M F, Baldassano C, Dube B. Premenstrual dysphoric disorder and psychiatric co-morbidity. Arch Womens Ment Health 2004; 7: 37–47
   PubMedGoogle Scholar
• Pearlstein T B, Frank E, Rivera-Tovar A, Thoft J S, Jacobs E, Mieczkowski T A. Prevalence of AxisII Axis I disorders in women with late luteal phase dysphoric disorder. J Affect Disord 1990; 20: 129–34
   PubMed Web of Science ®Google Scholar
• Halbreich U, Endicott J. Relationship of dysphoric premenstrual changes to depressive disorders. Acta Psychiatr Scand 1985; 71: 331–8
   PubMed Web of Science ®Google Scholar
• Endicott J, Halbreich U, Schacht S, Nee J. Premenstrual changes and affective disorders. Psychosom Med 1981; 43: 519–29
   PubMed Web of Science ®Google Scholar
• Mackenzie T B, Wilcox K, Baron H. Lifetime prevalence of psychiatric disorders in women with perimenstrual difficulties. J Affect Disord 1986; 10: 15–9
   PubMed Web of Science ®Google Scholar
• Fava M, Pedrazzi F, Guaraldi G P, Giovanni R, Genazzani A R, Facchinetti F. Comorbid anxiety and depression among patients with late luteal phase dysphoric disorder. J Anxiety Disord 1992; 6: 325–35
   Web of Science ®Google Scholar
• Critchlow D, Bond A J, Wingrove J. Mood disorder history and personality assessment in premenstrual dysphoric disorder. J Clin Psychiatry 2001; 62: 688–93
   PubMed Web of Science ®Google Scholar
• De Ronchi D, Muro A, Marziani A, Rucci P. Personality disorders and depressive symptoms in late luteal phase dysphoric disorder. Psychother Psychosom 2000; 69: 27–34
   PubMed Web of Science ®Google Scholar
• Maskall D D, Lam R W, Misri S, et al. Seasonality of symptoms in women with late luteal phase dysphoric disorder. J Am Psychiatry 1997; 154: 1436–41
   Google Scholar
• Praschak-Rieder N, Willeit M, Neumeister A, et al. Prevalence of premenstrual dysphoric disorder in female patients with seasonal affective disorder. J Affect Disord 2001; 63: 239–42
   PubMed Web of Science ®Google Scholar
• Graze K K, Nee J, Endicott J. Premenstrual depression predicts future major depressive disorder. Acta Psychiatr Scand 1990; 81: 201–5
   PubMed Web of Science ®Google Scholar
• Hartlage S A, Arduino K E, Gehlert S. Premenstrual dysphoric disorder and risk for major depressive disorder: a preliminary study. J Clin Psychol 2001; 57: 1571–8
   Google Scholar
• Richards M, Rubinow D, Daly R, Schmidt P. Premenstrual symptoms and perimenopausal depression. J Am Psychiatry 2006; 163: 133–7
   PubMed Web of Science ®Google Scholar
• Bloch M, Schmidt P, Danaceau M, Murphy J, Nieman L, Rubinow D. Effects of gonadal steroids in women with a history of postpartum depression. J Am Psychiatry 2000; 157: 924–30
   PubMed Web of Science ®Google Scholar
• Miller M N, Miller B E. Premenstrual exacerbations of mood disorders. Psychopharmacol Bull 2001; 35: 135–49
   PubMedGoogle Scholar
• Joffe H, Petrillo L F, Viguera A C, et al. Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: a preliminary report. J Clin Psychiatry 2007; 68: 1954–62
   PubMed Web of Science ®Google Scholar
• Harvey A T, Silkey B S, Kornstein S G, Clary C M. Acute worsening of chronic depression during a double-blind, randomized clinical trial of antidepressant efficacy: differences by sex and menopausal status. J Clin Psychiatry 2007; 68: 951–8
   Google Scholar
• Kornstein S G, Harvey A T, Rush A J, et al. Self-reported premenstrual exacerbation of depressive symptoms in patients seeking treatment for major depression. Psychol Med 2005; 35: 683–92
   PubMed Web of Science ®Google Scholar
• Yonkers K A, White K. Premenstrual exacerbation of depression: one process or two?. J Clin Psychiatry 1992; 53: 289–92
   PubMed Web of Science ®Google Scholar
• Hardoy M C, Serra M, Carta M G, Contu P, Pisu M G, Biggio G. Increased neuroactive steroid concentrations in women with bipolar disorder or major depressive disorder. J Clin Psychopharmacol 2006; 26: 379–84
   PubMedGoogle Scholar
• Hartlage S A, Brandenburg D L, Kravitz H M. Premenstrual exacerbation of depressive disorders in a community-based sample in the United States. Psychosom Med 2004; 66: 698–706
   Google Scholar
• Hsiao M C, Liu C Y, Chen K C, Hsieh T T. Characteristics of women using a mental health clinic in a gynecologic out-patient setting. Psychiatry Clin Neurosci 2002; 56: 459–63
   PubMed Web of Science ®Google Scholar
• Payne J L, Roy P S, Murphy-Eberenz K, et al. Reproductive cycle-associated mood symptoms in women with major depression and bipolar disorder. J Affect Disord 2007; 99: 221–9
   PubMed Web of Science ®Google Scholar
• Landen M, Eriksson E. How does premenstrual dysphoric disorder relate to depression and anxiety disorders?. Depress Anxiety 2003; 17: 122–9
   PubMed Web of Science ®Google Scholar
• Yonkers K A. Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders. J Clin Psychiatry 1997; 58: 62–7
   PubMed Web of Science ®Google Scholar
• Vulink N C, Denys D, Bus L, Westenberg H G. Female hormones affect symptom severity in obsessive-compulsive disorder. Int Clin Psychopharmacol 2006; 21: 171–5
   PubMed Web of Science ®Google Scholar
• Baker F C, Kahan T L, Trinder J, Colrain I M. Sleep quality and the sleep electroencephalogram in women with severe premenstrual syndrome. Sleep 2007; 30: 1283–91
   PubMed Web of Science ®Google Scholar
• Halbreich U, O'Brien P M, Eriksson E, Backstrom T, Yonkers K A, Freeman E W. Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?. CNS Drugs 2006; 20: 523–47
   PubMed Web of Science ®Google Scholar
• Wyatt K, Dimmock P, O'Brien P. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2002, (4):CD001396
   Google Scholar
• Yonkers K, Clark R, Trivedi M. The psychopharmacological treatment of nonmajor mood disorders. Karger, Basel 1997
   Google Scholar
• Eriksson E, Hedberg M, Andersch B, Sundblad C. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995; 12: 167–76
   PubMed Web of Science ®Google Scholar
• Ozeren S, Corakci A, Yucesoy I, Mercan R, Ethan G. Fluoxetine in the treatment of premenstrual syndrome. J Eur Obstet Gynecol Reprod Biol 1997; 73: 167–70
   PubMed Web of Science ®Google Scholar
• Menkes D B, Taghavi E, Mason P A, Spears G FS, Howard R C. Fluoxetine treatment of severe premenstrual syndrome. Br J Med 1992; 305: 346–7
   PubMed Web of Science ®Google Scholar
• Su T-P, Schmidt P, Danaceau M, et al. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology 1997; 16: 346–56
   PubMed Web of Science ®Google Scholar
• Wood S H, Mortola J F, Chan Y F, Moossazadeh F, Yen S S. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet Gynecol 1992; 80: 339–44
   PubMed Web of Science ®Google Scholar
• Steiner M, Korzekwa M, Lamont J, Wilkins A. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull 1997; 33: 771–4
   PubMed Web of Science ®Google Scholar
• Sundblad C, Hedberg M, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 1993; 9: 133–45
   PubMed Web of Science ®Google Scholar
• Sundblad C, Modigh K, Andersch B, Eriksson E. Clomipraine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand 1992; 85: 39–47
   PubMed Web of Science ®Google Scholar
• Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?. J Clin Psychopharmacol 1998; 18: 390–8
   PubMed Web of Science ®Google Scholar
• Ravindran L N, Woods S A, Steiner M, Ravindran A V. Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): a case series. Arch Womens Ment Health 2007; 10: 125–7
   Google Scholar
• Eriksson E MD, Ekman A P, Sinclair S MD, et al. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. J Clin Psychopharmacol 2008; 28: 195–202
   PubMed Web of Science ®Google Scholar
• Pearlstein T, Stone A, Lund S, Scheft H, Zlotnick C, Brown W. Comparison of fluoxetine, buproprion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 1997; 17: 261–5
   PubMed Web of Science ®Google Scholar
• Steiner M, Brown E, Trzepacz P, et al. Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder. Arch Womens Ment Health 2003; 6: 71–7
   PubMedGoogle Scholar
• Stone A, Pearlstein T, Brown W. Fluoxetine in the treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1991; 52: 290–3
   PubMed Web of Science ®Google Scholar
• Cohen L, Miner C, Brown E, et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002; 100: 435–44
   PubMed Web of Science ®Google Scholar
• Miner C, Brown E, McCray S, Gonzales J, Wohlreich M. Weekly luteal phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002; 24: 417–33
   PubMed Web of Science ®Google Scholar
• Yonkers K A, Halbreich U, Freeman E W, Brown C S, Pearlstein T B. Sertraline in the treatment of premenstrual dysphoric disorder. Psychopharmacol Bull 1996; 32: 41–6
   Google Scholar
• Freeman E, Sondheimer S, Polansky M, Garcia-Espagna B. Predictors of response to sertraline treatment of severe premenstrual syndromes. J Clin Psychiatry 2000; 61: 579–84
   PubMedGoogle Scholar
• Cohen L, Soares C, Yonkers K, Bellew K, Bridges I, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom Med 2004; 66: 707–13
   PubMed Web of Science ®Google Scholar
• Steiner M, Hirschberg A, Bergeron R, Holland F, Gee M, VanErp E. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. J Am Obstet Gynecol 2005; 193: 352–60
   PubMed Web of Science ®Google Scholar
• Yonkers K, Holthausen G, Poschman K, Howell H. Symptom-onset treatment for women with premenstrual dysphoric disorder. J Clin Psychopharmacol 2006; 26: 198–202
   PubMed Web of Science ®Google Scholar
• Landen M, Nissbrandt H, Allgulander C, Sorvik K, Ysander C, Eriksson E. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 2007; 32: 153–61
   PubMed Web of Science ®Google Scholar
• Freeman E, Rickels K, Yonkers K, et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001; 98: 737–44
   PubMed Web of Science ®Google Scholar
• Cohen L, Soares C, Lyster A, Cassano P, Brandes M, Leblanc G. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 2004; 24: 540–3
   Google Scholar
• Freeman E, Rickels K, Sondheimer S, Polansky M, Xiao S. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. J Am Psychiatry 2004; 161: 343–51
   PubMed Web of Science ®Google Scholar
• Eriksson E, Endicott J, Andersch B, et al. New perspectives on the treatment of premenstrual syndrome and premenstrual dysphoric disorder. Arch Womens Ment Health 2002; 4: 111–9
   Google Scholar
• Steiner M, Pearlstein T, Cohen L S, et al. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Womens Health (Larchmt) 2006; 15: 57–69
   PubMed Web of Science ®Google Scholar
• Freeman E, Rickels K, Sondheimer S, Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphonic disorder: a randomised controlled trial. Arch Gen Psychiatry 1999; 56: 932–9
   PubMed Web of Science ®Google Scholar
• Halbreich U, Kahn L. Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline. Expert Opin Pharmacother 2003; 4: 2065–78
   PubMed Web of Science ®Google Scholar
• Jermain D, Preece C, Sykes R, Kuehl T, Sulak P. Luteal phase sertraline treatment for premenstrual dysphoric disorder: results of a double-blind, placebo-controlled, crossover study. Arch Fam Med 1999; 8: 328–32
   PubMedGoogle Scholar
• Young S, Hurt P, Benedeck D, Howard R. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomised, double-blind, placebo controlled crossover trial. J Clin Psychiatry 1998; 59: 76–80
   PubMed Web of Science ®Google Scholar
• Yonkers K A, Pearlstein T, Fayyad R, Gillespie J A. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. J Affect Disord 2005; 85: 317–21
   PubMed Web of Science ®Google Scholar
• Halbreich U, Smoller J W. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997; 58: 399–402
   PubMed Web of Science ®Google Scholar
• Halbreich U, Bergeron R, Yonkers K, Freeman E, Stout A, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002; 100: 1219–29
   PubMed Web of Science ®Google Scholar
• Freeman E W, Sondheimer S J, Sammel M D, Ferdousi T, Lin H. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J Clin Psychiatry 2005; 66: 769–73
   PubMed Web of Science ®Google Scholar
• Kornstein S G, Pearlstein T B, Fayyad R, Farfel G M, Gillespie J A. Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies. J Clin Psychiatry 2006; 67: 1624–32
   Google Scholar
• Sundblad C, Wikander I, Andersch B, Eriksson E. A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side effects during ten cycles of treatment. Eur Neuropsychopharmacol 1997; 7: 201–6
   PubMed Web of Science ®Google Scholar
• Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment: double-blind placebo-controlled trial. J Br Psychiatry 2000; 176: 363–8
   PubMed Web of Science ®Google Scholar
• Rosenbaum J, Fava M, Hoog S, Ascroft R, Krebs W. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44: 77–87
   PubMed Web of Science ®Google Scholar
• Judge R, Parry M, Quail D, Jacobson J. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol 2002; 17: 217–25
   PubMed Web of Science ®Google Scholar
• Steiner M, Haskett R, Osmun J, Carroll B. Treatment of premenstrual tension with lithium carbonate. A pilot study. Acta Psychiatr Scand 1980; 61: 96–102
   PubMed Web of Science ®Google Scholar
• Freeman E W, Rickels K, Sondheimer S J, Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry 1999; 56: 932–9
   PubMed Web of Science ®Google Scholar
• Rickels K, Freeman E, Sondheimer S. Buspirone in treatment of premenstrual syndrome. Lancet 1989; 4: 777
   Google Scholar
• Smith S, Rinehart J, Ruddock V, Schiff I. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol 1987; 70: 37–43
   PubMed Web of Science ®Google Scholar
• Harrison W, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam. Arch Gen Psychiatry 1990; 47: 270–5
   PubMed Web of Science ®Google Scholar
• Freeman E, Rickels K, Sondheimer S, Polansky M. A double-blind trail of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995; 274: 51–7
   PubMed Web of Science ®Google Scholar
• Usman S, Indusekhar R, O'Brien S. Hormonal management of premenstrual syndrome. Best Pract Res Clin Obstet Gynaecol 2008; 22: 251–60
   PubMed Web of Science ®Google Scholar
• Dhar V, Murphy B. Double-blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology 1990; 15: 489–93
   PubMed Web of Science ®Google Scholar
• Leather A, Studd J, Watson N, Holland E. The treatment of severe premenstrual syndrome with goserelin with and without “add-back” estrogen therapy: a placebo-controlled study. Gynecol Endocrinol 1999; 13: 48–55
   PubMed Web of Science ®Google Scholar
• Di Carlo C, Palomba S, Tommaselli G, Guida M, Sardo A, Nappi C. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertil Steril 2001; 75: 380–4
   PubMed Web of Science ®Google Scholar
• Halbreich U, Rojansky N, Palter S. Elimination of ovulation and menstrual cyclicity (with danazol) improves dysphoric premenstrual syndromes. Fertil Steril 1991; 56: 1066–9
   PubMed Web of Science ®Google Scholar
• Deeny M, Hawthorn R, McKay-Hart D. Low dose danazol in the treatment of the premenstrual syndrome. Postgrad J Med 1991; 67: 450–4
   PubMedGoogle Scholar
• Sarno A, Miller E, Lundblad E. Premenstrual syndrome: beneficial effects of periodic, low-dose danazol. Obstet Gynecol 1987; 70: 33–6
   PubMed Web of Science ®Google Scholar
• Day J. Danazol and premenstrual syndrome. Postgrad J Med 1979; 55: 87–9
   PubMed Web of Science ®Google Scholar
• Watts J, Butt W, Edwards R. A clinical trial using danazol for the treatment of premenstrual tension. J Br Obstet Gynaecol 1987; 94: 30–4
   PubMedGoogle Scholar
• Hahn P M, Van Vugt D A, Reid R L. A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology 1995; 20: 193–209
   PubMed Web of Science ®Google Scholar
• Magos A, Brincat M, Studd J. Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo-controlled study. Br J Med (Clin Res Ed) 1986; 292: 1629
   PubMed Web of Science ®Google Scholar
• Watson N R, Studd J W, Savvas M, Baber R J. The long-term effects of estradiol implant therapy for the treatment of premenstrual syndrome. Gynecol Endocrinol 1990; 4: 99–107
   PubMed Web of Science ®Google Scholar
• Watson N, Studd J, Savvas M, Garnett T, Baber R. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989; 2: 730–2
   PubMed Web of Science ®Google Scholar
• Domoney C, Panay N, Hawkins A, Studd J. Treatment of premenstrual syndrome with transdermal oestrogen. J Int Gynaecol Obstet 2003; 83(suppl 3)37
   Google Scholar
• Wildemeersch D, Dhont M. Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. J Am Obstet Gynecol 2003; 188: 1297–8
   PubMed Web of Science ®Google Scholar
• Bancroft J, Rennie D. The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving and other symptoms. J Psychosom Res 1993; 37: 195–202
   PubMed Web of Science ®Google Scholar
• Graham C A, Sherwin B B. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992; 36: 257–66
   PubMed Web of Science ®Google Scholar
• Sulak P, Scow R, Preece C, Riggs M, Kuehl T. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95: 261–6
   PubMed Web of Science ®Google Scholar
• Sulak P, Kuehl T, Ortiz M, Schull B. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. J Am Obstet Gynecol 2002; 186: 1142–9
   PubMed Web of Science ®Google Scholar
• Freeman E W. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder. J Eur Contracept Reprod Health Care 2002; 7(suppl 3)27–34
   PubMed Web of Science ®Google Scholar
• Lopez L, Kaptein A, Helmerhorst F. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev Jan, 2008; 23(1), CD006586
   Google Scholar
• Rapkin A J, Winer S A. Drospirenone: a novel progestin. Exp Opin Pharmacother 2007; 8: 989–99
   PubMed Web of Science ®Google Scholar
• Yonkers K, Brown C, Pearlstein T, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106: 492–501
   PubMed Web of Science ®Google Scholar
• Pearlstein T, Bachmann G, Zacur H, Yonkers K. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72: 414–21
   PubMed Web of Science ®Google Scholar
• Rubig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climateric 2003; 6: 49–54
   PubMedGoogle Scholar
• Eriksson E, Sundblad C, Lisjo P, Modigh K, Andersch B. Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls. Psychoneuroendocrinology 1992; 17: 195–204
   PubMed Web of Science ®Google Scholar
• Krasnik C, Montori V M, Guyatt G H, Heels-Ansdell D, Busse J W. The effect of bright light therapy on depression associated with premenstrual dysphoric disorder. J Am Obstet Gynecol 2005; 193: 658–61
   Google Scholar
• Lam R W, Carter D, Misri S, Kuan A J, Yatham L N, Zis A P. A controlled study of light therapy in women with late luteal phase dysphoric disorder. Psychiatry Res 1999; 86: 185–92
   PubMed Web of Science ®Google Scholar
• Parry B L, Berga S L, Mostofi N, Sependa P A, Kripke D F, Gillin J C. Morning versus evening bright light treatment of late luteal phase dysphoric disorder. J Am Psychiatry 1989; 146: 1215–7
   PubMed Web of Science ®Google Scholar
• Vellacott I, Shroff N, Pearce M, Stratford M, Akbar F. A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome. Curr Med Res Opin 1987; 10: 450–6
   PubMed Web of Science ®Google Scholar
• Aslaksen K, Falk V. Spironolactone in the treatment of premenstrual tension: a double-blind study of spironolactone vs. bendroflumethiazide and placebo. Curr Ther Res Clin Exp 1991; 49: 120–30
   Google Scholar
• Wang M, Hammarback S, Lindhe B A, Backstrom T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand 1995; 74: 803–8
   PubMed Web of Science ®Google Scholar
• Wyatt K M, Dimmock P W, Jones P W, Shaughn O'Brien P M. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ 1999; 318: 1375–81
   PubMed Web of Science ®Google Scholar
• London R, Bradley L, Chiamori N. Effect of nutritional supplement on premenstrual symptomatology in women with premenstrual syndrome: a double-blind longitudinal study. J Am Coll Nutr 1991; 10: 494–9
   PubMed Web of Science ®Google Scholar
• Thys-Jacobs S. Micronutrients and the premenstrual syndrome: the case for calcium. J Am Coll Nutr 2000; 19: 220–7
   PubMed Web of Science ®Google Scholar
• Thys-Jacobs S, Ceccarelli S, Bierman A, Weisman H, Cohen M, Alvir J. Calcium supplementation in premenstrual syndrome: a randomized crossover trial. J Gen Intern Med 1989; 4: 183–9
   PubMed Web of Science ®Google Scholar
• Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. J Am Obstet Gynecol 1998; 179: 444–52
   PubMed Web of Science ®Google Scholar
• Walker A F, De Souza M C, Vickers M F, Abeyasekera S, Collins M L, Trinca L A. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health 1998; 7: 1157–65
   PubMed Web of Science ®Google Scholar
• Khine K, Rosenstein D L, Elin R J, Niemela J E, Schmidt P J, Rubinow D R. Magnesium (Mg) retention and mood effects after intravenous Mg infusion in premenstrual dysphoric disorder. Biol Psychiatry 2006; 59: 327–33
   Google Scholar
• Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ 2001; 322: 134–7
   PubMed Web of Science ®Google Scholar
• Berger D, Schaffner W, Schrader E, Meier B, Brattstrom A. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Arch Gynecol Obstet 2000; 264: 150–3
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol 2003; 18: 191–5
   PubMed Web of Science ®Google Scholar
• Loch E G, Selle H, Boblitz N. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. J Womens Health Gend Based Med 2000; 9: 315–20
   PubMedGoogle Scholar
• Budeiri D, Li Wan Po A, Dornan J. Is evening primrose oil of value in the treatment of premenstrual syndrome?. Control Clin Trials 1996; 17: 60–8
   PubMedGoogle Scholar
• Tesch B J. Herbs commonly used by women: an evidence-based review. J Am Obstet Gynecol 2003; 188(5 suppl)S44–55
   PubMedGoogle Scholar
• Stevinson C, Ernst E. A pilot study of Hypericum perforatum for the treatment of premenstrual syndrome. BJOG 2000; 107: 870–6
   Google Scholar
• Rossignol A M, Bonnlander H. Caffeine-containing beverages, total fluid consumption, and premenstrual syndrome. J Am Public Health 1990; 80: 1106–10
   PubMedGoogle Scholar
• Sayegh R, Schiff I, Wurtman J, Spiers P, McDermott J, Wurtman R. The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. Obstet Gynecol 1995; 86: 520–8
   PubMed Web of Science ®Google Scholar
• Freeman E, Stout A, Endicott J, Spiers P. Treatment of premenstrual syndrome with a carbohydrate-rich beverage. J Int Gynecol Obstet 2002; 77: 253–4
   Google Scholar
• Steege J, Blumenthal J. The effects of aerobic exercise on premenstrual symptoms in middle-aged women: a preliminary study. J Psychosom Res 1993; 37: 127–33
   PubMed Web of Science ®Google Scholar
• Hunter M, Ussher J, Browne S, Cariss M, Jelley R, Katz M. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002; 23: 193–9
   PubMed Web of Science ®Google Scholar
• Hunter M S, Ussher J M, Cariss M, Browne S, Jelley R, Katz M. Medical (fluoxetine) and psychological (cognitive-behavioural therapy) treatment for premenstrual dysphoric disorder: a study of treatment processes. J Psychosom Res 2002; 53: 811–7
   PubMed Web of Science ®Google Scholar
• Blake F, Salkovskis P, Gath D, Day A, Garrod A. Cognitive therapy for premenstrual syndrome: a controlled trial. J Psychosom Res 1998; 45: 307–18
   PubMed Web of Science ®Google Scholar
• Christensen A P, Oei T P. The efficacy of cognitive behaviour therapy in treating premenstrual dysphoric changes. J Affect Disord 1995; 33: 57–63
   PubMed Web of Science ®Google Scholar
• Mira M, McNeil D, Fraser I, Vizzard J, Abraham S. Mefenamic acid in the treatment of premenstrual syndrome. Obstet Gynecol 1986; 68: 395–8
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Fioroni L, Sances G, Romano G, Nappi G, Genazzani A. Naproxen sodium in the treatment of premenstrual symptoms. A placebo-controlled study. Gynecol Obstet Invest 1989; 28: 205–8
   PubMed Web of Science ®Google Scholar
• Chuong C, Hsi P. Effect of naloxone on luteinizing hormone secretion in premenstrual syndrome. Fertil Steril 1994; 61: 1039–44
   PubMedGoogle Scholar
• Young E, Korszun A. Psychoneuroendocrinology of depression. Hypothalamic pituitary-gonadal axis. Psychiatr Clin North Am 1998; 21: 309–23
   PubMedGoogle Scholar